However, the viral infections also are related with diseases in the CNS characterized by the presence of leukocyte infiltration and inflammation, inducing a progressive damage [1], such as the progressive multifocal leukoencephalopathy with the John Cunningham virus (JC), AIDS-related dementia complex observed in HIV-1-infected patients, neurodevelopmental sequelae (mental retardation, cerebral palsy, and sensorineural hearing loss) caused by congenital cytomegalovirus (CMV) infection or cerebral mass lesions in immunocompromised adults CMV-infected, and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) that affects the human T-cell lymphotropic virus type 1 (HTLV-1)-infected individuals
Heres a step-by-step guide on everything you need to know about this treatment
The formula: Volume to add (mL) = Peptide mass (mg) divided by Desired concentration (mg/mL) Example: Fill weight from COA: 5.00 mg Desired working concentration: 2 mg/mL Volume to add: 5.00 divided by 2.00 = 2.50 mL bacteriostatic water Common working concentrations used in CJC-1295 research protocols range from 0.5 mg/mL to 2 mg/mL, depending on experimental design and aliquot volume requirements
The website can be easily navigated, products are easy to find, and theres tons of information